Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.
Robin C, Rollot F, Lefort M, Casey R, Vukusic S, Mathey G, Ciron J, De Seze J, Stankoff B, Maillart E, Ruet A, Labauge PM, Kwiatkowski A, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Casez O, Bourre B, Wahab A, Magy L, Moulin S, Camdessanche JP, Doghri I, Sarov M, Hankiewicz K, Pottier C, Dos Santos A, Manchon E, Tchikviladze M, Nifle C, Kerbrat A, Edan G, Le Page E, Michel L; as the OFSEP Investigators.
Robin C, et al. Among authors: sarov m.
Neurology. 2025 Aug 12;105(3):e213744. doi: 10.1212/WNL.0000000000213744. Epub 2025 Jul 16.
Neurology. 2025.
PMID: 40669026